BR112020005964A2 - intermediário de linagliptina cristalina e processo para preparação de linagliptina - Google Patents
intermediário de linagliptina cristalina e processo para preparação de linagliptina Download PDFInfo
- Publication number
- BR112020005964A2 BR112020005964A2 BR112020005964-1A BR112020005964A BR112020005964A2 BR 112020005964 A2 BR112020005964 A2 BR 112020005964A2 BR 112020005964 A BR112020005964 A BR 112020005964A BR 112020005964 A2 BR112020005964 A2 BR 112020005964A2
- Authority
- BR
- Brazil
- Prior art keywords
- formula
- linagliptin
- crystalline form
- reaction mass
- linagliptin intermediate
- Prior art date
Links
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 title claims abstract description 50
- 229960002397 linagliptin Drugs 0.000 title claims abstract description 49
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- 238000000034 method Methods 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 239000012296 anti-solvent Substances 0.000 claims 3
- 238000010438 heat treatment Methods 0.000 claims 3
- 239000002904 solvent Substances 0.000 claims 3
- 239000000523 sample Substances 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 9
- 238000000634 powder X-ray diffraction Methods 0.000 description 9
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000008186 active pharmaceutical agent Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000013019 agitation Methods 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- -1 4-methyl-2-quinazolinyl Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- FAIAJSOSTNJZCI-UHFFFAOYSA-N purine-2,6-dione Chemical compound O=C1NC(=O)C2=NC=NC2=N1 FAIAJSOSTNJZCI-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 238000001144 powder X-ray diffraction data Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 229940049667 tradjenta Drugs 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Emergency Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201741034292 | 2017-09-27 | ||
| IN201741034292 | 2017-09-27 | ||
| PCT/IB2018/057484 WO2019064214A1 (en) | 2017-09-27 | 2018-09-27 | INTERMEDIATE OF CRYSTALLINE LINAGLIPTIN AND PROCESS FOR THE PREPARATION OF LINAGLIPTIN |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112020005964A2 true BR112020005964A2 (pt) | 2020-10-06 |
Family
ID=65903063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112020005964-1A BR112020005964A2 (pt) | 2017-09-27 | 2018-09-27 | intermediário de linagliptina cristalina e processo para preparação de linagliptina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11040974B2 (enExample) |
| JP (1) | JP2020535193A (enExample) |
| KR (1) | KR20200092946A (enExample) |
| CN (1) | CN111511743A (enExample) |
| AU (1) | AU2018343236A1 (enExample) |
| BR (1) | BR112020005964A2 (enExample) |
| CA (1) | CA3076980A1 (enExample) |
| MX (1) | MX2020004050A (enExample) |
| RU (1) | RU2020114890A (enExample) |
| WO (1) | WO2019064214A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110684026A (zh) * | 2019-10-24 | 2020-01-14 | 扬子江药业集团上海海尼药业有限公司 | 一种利格列汀的工业化制备方法 |
| CN110872292B (zh) * | 2019-11-30 | 2022-01-25 | 江苏君若药业有限公司 | 一条合成糖尿病药物利拉利汀的路线 |
| EP4349837A1 (en) | 2022-10-05 | 2024-04-10 | Zaklady Farmaceutyczne "Polpharma" S.A. | A pharmaceutical intermediate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| BRPI0711558A2 (pt) | 2006-05-04 | 2011-11-08 | Boeringer Ingelheim Internat Gmbh | polimorfos |
| IN2013MU02055A (enExample) * | 2013-06-18 | 2015-07-03 | Cadila Healthcare Ltd | |
| WO2015011609A1 (en) * | 2013-07-23 | 2015-01-29 | Ranbaxy Laboratories Limited | Process for the preparation of linagliptin and an intermediate thereof |
-
2018
- 2018-09-27 WO PCT/IB2018/057484 patent/WO2019064214A1/en not_active Ceased
- 2018-09-27 MX MX2020004050A patent/MX2020004050A/es unknown
- 2018-09-27 CA CA3076980A patent/CA3076980A1/en active Pending
- 2018-09-27 JP JP2020517938A patent/JP2020535193A/ja active Pending
- 2018-09-27 KR KR1020207012196A patent/KR20200092946A/ko not_active Ceased
- 2018-09-27 CN CN201880076836.6A patent/CN111511743A/zh active Pending
- 2018-09-27 AU AU2018343236A patent/AU2018343236A1/en not_active Abandoned
- 2018-09-27 RU RU2020114890A patent/RU2020114890A/ru unknown
- 2018-09-27 BR BR112020005964-1A patent/BR112020005964A2/pt not_active Application Discontinuation
-
2020
- 2020-03-27 US US16/832,067 patent/US11040974B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3076980A1 (en) | 2019-04-04 |
| US11040974B2 (en) | 2021-06-22 |
| KR20200092946A (ko) | 2020-08-04 |
| AU2018343236A1 (en) | 2020-05-14 |
| MX2020004050A (es) | 2020-11-06 |
| RU2020114890A (ru) | 2021-10-27 |
| JP2020535193A (ja) | 2020-12-03 |
| US20200354363A1 (en) | 2020-11-12 |
| WO2019064214A1 (en) | 2019-04-04 |
| CN111511743A (zh) | 2020-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2985277B1 (en) | Method for preparing an atropisomer of a pyrrole derivative | |
| EP4570805A1 (en) | Tricyclic compounds and medical use thereof | |
| JP7036846B2 (ja) | Ｃｄｋ阻害剤の結晶質形態 | |
| AU2016258388B2 (en) | Novel crystal of uracil compound | |
| JP2018520205A (ja) | レンバチニブメシル酸塩の新規結晶形及びその製造方法 | |
| EP3315499A1 (en) | CRYSTAL OF (6S,9aS)-N-BENZYL-6-[(4-HYDROXYPHENYL)METHYL]- 4,7-DIOXO-8-({6-[3-(PIPERAZIN-1-YL)AZETIDIN-1-YL]PYRIDIN- 2-YL}METHYL)-2-(PROP-2-EN-1-YL)-OCTAHYDRO-1H-PYRAZINO[2,1-c][1,2,4]TRIAZINE-1-CARBOXAMIDE COMPOUND | |
| WO2017092413A1 (zh) | 一种二氨基嘧啶化合物及包含该化合物的组合物 | |
| JP6193762B2 (ja) | １−｛（２Ｓ）−２−アミノ−４−［２，４−ビス（トリフルオロメチル）−５，８−ジヒドロピリド［３，４−ｄ］ピリミジン−７（６Ｈ）−イ | |
| JP2023511105A (ja) | ２－［３－［４－アミノ－３－（２－フルオロ－４－フェノキシ－フェニル）－１ｈ－ピラゾロ［３，４－ｄ］ピリミジン－１－イル］ピペリジン－１－カルボニル］－４－メチル－４－［４－（オキセタン－３－イル）ピペラジン－１－イル］ペンタ－２－エンニトリルの結晶形態 | |
| BR112015017963A2 (pt) | composto de fenil amino pirimidina deuterado, método para preparar a composição farmacêutica, composição farmacêutica e uso do composto | |
| CA3130247A1 (en) | Fgfr inhibitor compound in solid form and preparation method therefor | |
| BR112020005964A2 (pt) | intermediário de linagliptina cristalina e processo para preparação de linagliptina | |
| CN119462648A (zh) | 四氢吡啶并嘧啶类化合物及其制备方法和应用 | |
| JP7618575B2 (ja) | Ｎ－（５－（（４－エチルピペラジン－１－イル）メチル）ピリジン－２－イル）－５－フルオロ－４－（３－イソプロピル－２－メチル－２ｈ－インダゾール－５－イル）ピリミジン－２－アミンおよびその塩の結晶形態および非晶質形態、ならびにその製造方法および治療的使用 | |
| CN112830919B (zh) | 苯并哌啶衍生物可药用盐及其制备方法 | |
| BR112020006051A2 (pt) | formas cristalinas de lenalidomida | |
| EP4644374A1 (en) | Naphthylamide compound, and preparation method therefor and use thereof | |
| HK40054619B (zh) | 吡咯并[2，3-d]嘧啶甲苯磺酸盐、其结晶形式以及有关的制备方法和中间体 | |
| HK1241358A1 (en) | Crystal of (s)-1-(2-hydroxyethyl)-4-methyl-n- [4-(methylsulfonyl)phenyl]-5-[2-(trifluoromethyl)phenyl]- 1h-pyrrole-3-carboxamide | |
| HK1221214B (en) | Method for preparing an atropisomer of a pyrrole derivative | |
| HK1187046B (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| HK1187046A (en) | Hydrate of 1-{(2s)-2-amino-4-[2,4-bis(trifluoromethyl)-5,8-di- hydropyrido[3,4-d]pyrimidin-7(6h)-yl]-4-oxobutyl}-5,5-difluoro-piperidin-2-one tartrate | |
| BR122020009305B1 (pt) | Forma cristalina de 6-(6-aminopirazin-2-il)-n-(4-(4-(oxetan-3-il)piperazin-1- il)fenil)imidazo[1,2-a]pirazin-8-amina, composição farmacêutica, e, uso de uma forma cristalina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |